Royalty Pharma Plc Stock Performance
as on April 10, 2026 at 3:08 am IST
Day's Low
Day's High
$47.44$48.34
1.80%
Downside
0.06%
Upside
52 Week's Low
52 Week's High
$30.04$49.0637.82%
Downside
1.55%
Upside
Royalty Pharma Plc share price movements today
- Previous Close
- $47.90
- Open
- $47.76
- Volume
- 657.5K
- Day's Low - High
- $47.44 - $48.34
- 52 Week Low - High
- $30.04 - $49.06
Royalty Pharma Plc Historical Returns
- 1 Month Return
- + 4.49 %
- 3 Month Return
- + 19.24 %
- 1 Year Return
- + 48.44 %
- 3 Year Return
- + 31.67 %
- 5 Year Return
- + 13.21 %
Royalty Pharma Plc Stock Fundamentals & Key Indicators
Check Royalty Pharma Plc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$27.1B
EPS (TTM)
5.0613
Dividend Yield
2.79%
Quarterly Earnings Growth YOY
0.09%
PE Ratio (TTM)
26.63
Industry PE ratio
20.559322033898304
PEG Ratio
2.7848
EBITDA
1.6B
Revenue (TTM)
2.4B
Profit Margin
32.42%
Return On Equity TTM
13.20%
Royalty Pharma Plc Stock Valuation
Track how Royalty Pharma Plc P/E has moved over time to understand its valuation trends.
Royalty Pharma Plc in the last 5 years
Lowest (5.79x)
December 31, 2023
Industry (20.56x)
April 9, 2026
Today (26.63x)
April 9, 2026
Highest (15.58x)
June 30, 2021
Today’s Price to Earnings Ratio: 26.63x
Royalty Pharma Plc vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Royalty Pharma Plc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $27.1B | 13.21% | 26.63 | 32.42% | |
| BUY | $34.6B | 405.3% | -16.34 | -210.54% | |
| BUY | $42.4B | 136.74% | 137.13 | 8.45% | |
| BUY | $109.8B | 108.07% | 28.17 | 32.94% | |
| BUY | $80.4B | 63.21% | 18.32 | 31.41% |
Stock Returns calculator for Royalty Pharma Plc Stock including INR - Dollar returns
The Royalty Pharma Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.
Investment Value
₹1,00,000
Royalty Pharma Plc investment value today
Current value as on today
₹1,60,031
Returns
₹60,031
(+60.03%)
Returns from Royalty Pharma Plc Stock
₹49,706 (+49.71%)
Dollar Impact
₹10,325 (+10.33%)
Analyst Recommendation on Royalty Pharma Plc Stock
Based on 14 analysts
85.71%
Buy
14.29%
Hold
0.00%
Sell
Based on 14 analysts, 85.71% of analysts recommend a 'BUY' rating for Royalty Pharma Plc. Average target price of $51.56
Royalty Pharma Plc Share Price Target
Get share price movements and forecasts by analysts on Royalty Pharma Plc.
What analysts predicted
6.3%UPSIDE
Target Price
$51.56
Current Price
$48.31
Analyzed by
14 Analysts
Target
$51.56
Royalty Pharma Plc target price $51.56, a slight upside of 6.3% compared to current price of $48.31. According to 14 analysts rating.
Royalty Pharma Plc Stock’s Investor Sentiment and Interest
Search interest for Royalty Pharma Plc Stock has increased by 3% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:3% versus previous 30 day period
Royalty Pharma Plc Quarterly Profit & Loss
All numbers in Millions USD
Royalty Pharma Plc Annual Profit & Loss
All numbers in Millions USD
Royalty Pharma Plc Quarterly Cash Flow
All numbers in Millions USD
Royalty Pharma Plc Annual Cash Flow
All numbers in Millions USD
Royalty Pharma Plc News & Key Events
Today's Timeline - 11 February
Wed, 06:13 PM
-Royalty Pharma reports strong Q4 and FY 2025 results, with significant growth in Portfolio Receipts and adjusted EBITDA.
Wed, 07:35 PM
-Royalty Pharma releases 2025 10-K report, highlighting strategic acquisitions and robust financial performance despite slight net income decrease.
Wed, 07:57 PM
-Royalty Pharma provides earnings guidance for 2026, expecting Portfolio Receipts between $3,275 million and $3,425 million.
Insights on Royalty Pharma Plc
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Royalty Pharma Plc has shown consistent growth in revenue over the last four quarters. Revenue increased from $568.24 million to $621.99 million, resulting in an average quarter-on-quarter increase of 3.0%. This trend indicates a positive financial performance for the company.
- POSITIVE IMPACT
Price Rise
In the last 3 months, RPRX stock has moved up by 19.2%
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, RPRX has outperformed top 5 stocks with highest market-cap in its industry
NO EFFECTAgainst Peers
In the last 1 year, Beone Medicines Ltd has given 51.3% return, outperforming this stock by 2.9%
NEGATIVE IMPACTProfit Down
Royalty Pharma Plc has experienced a decline in its net profit over the last two quarters. The net profit fell from $288.21 million to $214.20 million, reflecting an average decrease of 25.7% per quarter.
About Royalty Pharma Plc
| Organisation | Royalty Pharma Plc |
| Headquarters | 110 East 59th Street, New York, NY, United States, 10022 |
| Industry | Health Technology |
| CEO | Mr. Pablo Legorreta |
| E-voting on shares | Click here to vote |
Key Management of Royalty Pharma Plc
Name | Title |
|---|---|
Mr. George Grofik C.F.A., CPA | Senior VP and Head of Investor Relations & Communications |
Mr. Pablo Legorreta | Founder, Chairman of the Board & CEO |
Mr. Terrance P. Coyne | Executive VP & CFO |
Mr. Christopher Hite | Chairman of Partnering & Investments |
Mr. Ashwin Pai M.D. | Executive Vice President of Investments & Partnering |
Mr. Eric Cornelius Schneider | Senior VP & Chief Technology Officer |
Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive Vice President of Research & Investments |
Dr. James Folmar Reddoch Ph.D. | Executive VP of Investments & Chief Scientific Officer |
Mr. Arthur Richard McGivern J.D. | Executive VP & Chief Legal Officer |
Ms. Molly Sawaya | Executive VP & Head of Human Capital |
FAQs
What is Royalty Pharma Plc share price today?
Royalty Pharma Plc share price today is $48.31 as on . Royalty Pharma Plc share today touched a day high of $48.34 and a low of $47.44.
What is the 52 week high and 52 week low for Royalty Pharma Plc share?
Royalty Pharma Plc share touched a 52 week high of $49.06 on and a 52 week low of $30.04 on . Royalty Pharma Plc stock price today i.e. is trending at $48.31,which is 1.53% down from its 52 week high and 60.82% up from its 52 week low.
What is Royalty Pharma Plc's market capitalisation today?
Royalty Pharma Plc market capitalisation is $0.03T as on .
How to invest in Royalty Pharma Plc Stock (RPRX) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Royalty Pharma Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Royalty Pharma Plc Shares that will get you 0.0310 shares as per Royalty Pharma Plc share price of $48.31 per share as on April 9, 2026 at 9:38 pm IST.
What is the minimum amount required to buy Royalty Pharma Plc Stock (RPRX) from India?
Indian investors can start investing in Royalty Pharma Plc (RPRX) shares with as little as ₹92.637 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹926.37 in Royalty Pharma Plc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Royalty Pharma Plc share’s latest price of $48.31 as on April 9, 2026 at 9:38 pm IST, you will get 0.2070 shares of Royalty Pharma Plc. Learn more about
fractional shares .
What are the returns that Royalty Pharma Plc has given to Indian investors in the last 5 years?
Royalty Pharma Plc stock has given 13.21% share price returns and 24.53% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?